Week in Review: Luye May Stage $500 Million Singapore IPO of Healthcare Assets

Deals and Financings   Luye Medical may conduct a $500 million IPO of its healthcare assets on the Singapore exchange; ARMO BioSciences, a Bay Area immuno-oncology company, completed a $128 million IPO in the US after raising capital from China VCs; Tmunity of Philadelphia closed a $100 million Series A with Ping An a major investor to develop Crispr and other immuno-oncology candidates; Neuspera, a California neuromodulation company, raised $26 million in a B round, led by 6 Dimensions Capital of China ; XtalPi of Boston and Shenzhen closed a $15 million Series B funding led by Sequoia China , with Google and Tencent participating; Shanghai Pharma plans to open a San Diego office to expand its international M&A activity; Jixi Biotechnology will make an investment of several million dollars in Taiwan Liposome and form a JV to market TLC's products in China ; Harbour BioMed of Shanghai completed a Series A+ round of unspecified size from China venture capitalists; Trials and Approvals   Generon ( Shanghai ) reported its recombinant biologic for neutropenia met its primary efficacy endpoint in a China breast cancer trial; Amoy Diagnostics of Xiamen received CFDA approval for its plasma-based EGFR test; Company News   Chengdu 's Clover Biopharma announced plans to build a biologic drug manufacturing facility in Changxing, using GE's single use reactors; GlaxoSmithKline launched Triumeq, a triple-therapy HIV treatment, in China at a monthly price of $450; Government and Regulatory   China researchers have treated 86 cancer patients using Crispr-Cas9 tools to modify DNA to increase the patients' immune response. Stock Symbols: (NSDQ: ARMO) (NSDQ: GOOG) (HK: 0700) (SHA: 601607; HK: 2607) (TT: 4152) (SHZ: 300685) (NYSE: GSK) Share this with colleagues: // //